Pharma BD Deal Intelligence
Biogen's $7.3B all-cash acquisition of Reata Pharmaceuticals delivered SKYCLARYS, the first FDA-approved Friedreich's ataxia treatment, anchoring Biogen's rare-disease neurology push. Revenue scaled from ~$56M in partial-year 2023 to ~$371M in 2024, with a pediatric Phase 3 (BRAVE) now underway to extend the franchise.
Biogen acquired Reata Pharmaceuticals for ~$6.5B for rare disease portfolio.
Biogen outbid a rival large-cap pharma to claim Reata for $7.3 billion in a competitive bidding process, reflecting strong strategic interest in the rare…
Skyclarys global revenue was approximately $133 million in Q3 2025, representing 30% year-over-year growth.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Biogen acquired Reata Pharmaceuticals for $172.50 per share in cash, an enterprise value of approximately $7.3 billion, to gain SKYCLARYS (omaveloxolone) -- the first and only FDA-approved treatment for Friedreich's ataxia (FA). Announced July 28, 2023 and completed September 26, 2023 (~99.65% of votes cast approved the merger), the deal anchored Biogen's rare-disease neurology strategy. Skyclarys revenue ramped from ~$56M (2023, partial year) to ~$371M in 2024, with Q3 2025 global revenue ~$133M (+30% YoY). In June 2025 Biogen initiated the global Phase 3 BRAVE study evaluating omaveloxolone in pediatric FA patients (ages 2-<16).
Friedreich's ataxia (FA) is a newly-opened rare disease market where Skyclarys (omaveloxolone) holds first-mover advantage, but pipeline threats span distinct MOAs. Nrf2 activators (incumbent): omaveloxolone (Skyclarys, Biogen/Reata) received FDA approval February 2023 and EMA approval February 2024 as the first and only approved therapy for FA in patients 16+; 2023 Reata-reported sales were ~$42M from February-July, with Biogen reporting continued ramp. Gene therapy (AAV-based frataxin replacement): LX2006 (Lexeo Therapeutics; Phase 1/2 SUNRISE-FA for cardiomyopathy subset) and early-stage programs from Pfizer and Voyager; these address cardiac FA phenotype specifically. Frataxin upregulation/epigenetic: nicotinamide (Phase 2 academic) and resveratrol derivatives (early). Antioxidants/mitochondrial: idebenone (Raxone, Santhera; failed US FA development, approved in EU for LHON not FA) and coenzyme Q10 (supplement). Iron chelators: deferiprone (Ferriprox, Chiesi) was studied but the FACT trial suggested worsening; not recommended. Symptomatic: physiotherapy and cardioselective agents for cardiomyopathy. For Biogen, Skyclarys faces no near-term pharmacologic competitor through 2027; the key commercial threats are gene therapy disrupting the disease-modifying narrative and payer pushback on $370K annual pricing.
Diabetic peripheral neuropathic pain (DPNP) is a large, generic-dominated analgesic market where Reata's Hsp90 modulator cemdomespib competes against entrenched symptomatic therapies rather than disease-modifying agents. Alpha-2-delta ligands: pregabalin (Lyrica, Pfizer; generic since 2019) and gabapentin (Neurontin, generic) are first-line per ADA and AAN guidelines. SNRIs: duloxetine (Cymbalta, Lilly; generic since 2013) is FDA-approved for DPNP. Tricyclic antidepressants: amitriptyline (generic) is guideline-recommended off-label. Topical agents: capsaicin 8% patch (Qutenza, Averitas) is FDA-approved for DPNP (July 2020) and lidocaine 5% patch (Lidoderm, generic). Opioids: tapentadol ER (Nucynta ER, Collegium Pharmaceutical) is FDA-approved for DPNP. Emerging disease-modifying MOAs include SGLT2 inhibitors (class effects under study) and Hsp90/Sigma-1 modulators in development. Phase 3 competitors targeting underlying neuropathy pathology are limited; most late-stage programs remain symptomatic. For Biogen, cemdomespib's commercial threat is less about novel rivals and more about the generic analgesic floor: any branded launch requires either clear disease-modification (structural nerve regeneration) or substantially better tolerability vs. duloxetine/pregabalin. Payer barriers in this indication are substantial given $4-20/month generic alternatives.
Mitochondrial Dysfunction Diseases is an umbrella for heterogeneous rare disorders (Friedreich's ataxia, Leber's hereditary optic neuropathy, MELAS, CPEO, Barth syndrome). Approved/granted: Skyclarys (omaveloxolone, Biogen/Reata, Nrf2 activator; FDA-approved 2023 for Friedreich's ataxia, ~$200M 2024); Raxone (idebenone, Santhera; EMA-approved for LHON, not FDA). Investigational: elamipretide (SBT-272, Stealth; Phase 3 for Barth syndrome, primary missed); MTP-131 (Phase 3 nonarteritic ischemic optic neuropathy). Gene therapies (Ikarovec, GenSight) in development. Biogen's Reata acquisition motivated primarily by Skyclarys; broader mitochondrial portfolio is early-stage pipeline.
Biogen announced Reata deal for $7.3B while simultaneously executing workforce reductions.
Biogen acquired Reata to gain Skyclarys, first and only approved treatment for Friedreich ataxia.
Skyclarys grew from $56M in 2023 to ~$371M in 2024, with Q4 hitting $102M. Reflects financial performance following Biogen Inc.'s $6.5B acquisition of Reata Pharmaceuticals.
Biogen projected Skyclarys to be significantly accretive to earnings beginning 2025.
Biogen began the global Phase 3 BRAVE study of omaveloxolone (Skyclarys) in ~255 children with Friedreich ataxia aged 2 to <16, a label-expansion opportunity beyond the current 16+ approval.
Skyclarys global revenue reached approximately $133M in Q3 2025, up 30% year-over-year, confirming continued ramp of the Friedreich ataxia franchise acquired from Reata.
Strong Early Trajectory. Assessment of Biogen Inc.'s $6.5B acquisition of Reata Pharmaceuticals and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Biogen Inc. / Reata Pharmaceuticals (this deal) | 2023 | $7.3B | 73 |
| Biogen Inc. / Human Immunology Biosciences | 2024 | $1.1B | 68 |
| Biogen Inc. / RayThera Inc. | 2026 | $1.0B | 52 |
| Biogen Inc. / Bristol-Myers Squibb Company | 2017 | $710M | 15 |
| Biogen Inc. / Nightstar Therapeutics | 2019 | $800M | — |
| Biogen Inc. / TJ Biopharma Co., Ltd. | 2026 | $850M | — |
| Biogen Inc. / Vanqua Bio, Inc. | 2025 | $1.1B | — |
← Browse all deals · How we score deals
More: 2023 deals · Biogen Inc. deals · Neurology deals